Alrex
- Generic Name: loteprednol etabonate ophthalmic suspension
- Brand Name: Alrex
Alrex (Loteprednol Etabonate Ophthalmic Suspension) side effects drug center
Alrex Side Effects Center
What Is Alrex?
Alrex (loteprednol etabonate ophthalmic suspension) is a corticosteroid used to treat eye swelling caused by surgery, infection, allergies, and other conditions.
What Are Side Effects of Alrex?
Common side effects of Alrex include:
- minor stinging or burning when using the eye drops,
- temporary blurred vision,
- dry eyes,
- eye redness,
- itchy or watery eyes,
- feeling that something is in the eye,
- sensitivity to light,
- headache,
- runny nose, or
- sore throat.
Tell your doctor if you have serious side effects of Alrex including:
- signs of a new eye infection such as swelling, redness, irritation, or drainage;
- blurred vision, eye pain, or seeing halos around lights;
- problems with your vision; or
- severe pain, burning or stinging when using the eye drops.
Dosage for Alrex
The dose of Alrex is one drop instilled into the affected eye(s) four times daily.
What Drugs, Substances, or Supplements Interact with Alrex?
It is not likely other drugs you take orally or inject will interact with Alrex used in the eyes. But many drugs can interact with each other. Tell your doctor all medications and supplements you use.
Alrex During Pregnancy and Breastfeeding
During pregnancy, Alrex should be taken only if prescribed. It is unknown if it will harm a fetus. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.
Additional Information
Our Alrex (loteprednol etabonate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Alrex Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
- pain when using the eye drops;
- worsening redness or itching;
- eye pain or swelling, trouble closing your eye;
- pain behind your eyes, sudden vision changes;
- tunnel vision, seeing halos around lights; or
- signs of eye infection--redness, severe discomfort, crusting or drainage.
Common side effects may include:
- minor burning when using the eye drops;
- eye pain, blurred vision;
- dry or watery eyes;
- feeling like something is in your eye;
- your eyes may be more sensitive to light;
- headache; or
- runny nose, sore throat.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Alrex (Loteprednol Etabonate Ophthalmic Suspension)
Alrex Professional Information
SIDE EFFECTS
Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia. Other ocular adverse reactions occurring in less than 5% of patients include conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillae, and uveitis. Some of these events were similar to the underlying ocular disease being studied.
Non-ocular adverse reactions occurred in less than 15% of patients. These include headache, rhinitis and pharyngitis.
In a summation of controlled, randomized studies of individuals treated for 28 days or longer with loteprednol etabonate, the incidence of significant elevation of intraocular pressure ( ≥ 10 mm Hg) was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients receiving 1% prednisolone acetate and 0.5% (3/583) among patients receiving placebo. Among the smaller group of patients who were studied with ALREX, the incidence of clinically significant increases in IOP ( ≥ 10 mm Hg) was 1% (1/133) with ALREX and 1% (1/135) with placebo.
Read the entire FDA prescribing information for Alrex (Loteprednol Etabonate Ophthalmic Suspension)
&Copy; Alrex Patient Information is supplied by Cerner Multum, Inc. and Alrex Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.